Previsional Program (still subject to changes)

modified 1 October 2003

SUNDAY 21 MARCH 2004


17:00

Registration


17.30 Welcome address

17:45-18:15 Keynote lecture:
Charles J. ARNTZEN, Arizona State University, Tempe, USA

18:15-18:45 Keynote lecture:
Hilary KOPROWSKI, Jefferson University, Philadelphia, USA

19:30 Dinner


MONDAY 22 MARCH 2004

SESSION 1.- EXPRESSION OF FOREIGN PROTEINS IN PLANTS

Chairperson William O. DAWSON, University of Florida, Lake Alfred, USA

Transgenic Plants
09:00 Opportunities for recombinant antigen and antibody expression in transgenic plants; technology assessment
Stefan SCHILLBERG, Fraunhofer Institute for Molecular Biology, Aachen, Germany
09:20 Questions and answers

09:25 Post-translational processing in plants (including glycosylation)
Loïc FAYE, CNRS/University of Rouen, France

09:45 Questions and answers


09:50 Chloroplast genetic engineering for vaccine production
Henry DANIELL, University of Central Florida, Orlando, USA

10:10 Questions and answers

Viral vectors
10:15 Viral vectors for plant transgenesis
Paul AHLQUIST, University of Wisconsin, Madison, USA
10:35 Questions and answers

10:40 Break

11:10 Viral vectors for antigen/antibody gene transfection in plants
George LOMONOSSOFF, John Innes Centre, Norwich, UK
11:30 Questions and answers

11:35 Discussion: What criteria should be used to select the plant species used for vaccine and antibody production? Are there special needs in the developping world?

12.05:0 Lunch


SESSION 2.- MUCOSAL IMMUNIZATION,INDUCTION OF IMMUNITY/TOLERANCE/ALLERGY
BY ORAL ANTIGENS


Chairperson Michael W. RUSSELL, University of Buffalo, USA

13:30 Uptake and presentation of orally administered antigens
Maria RESCIGNO, European Institute of Oncology, Milan, Italy
13:50 Questions and answers

13:55 Immune responses to orally administered antigens
Allan M. MOWAT, University of Glasgow, UK
14:15 Questions and answers

14:20 Mechanisms of tolerance induction to orally administered antigens
Jiri MESTECKY, University of Alabama at Birmingham, USA
14:40 Questions and answers

14:45 Mucosal adjuvants
John D.CLEMENTS, Tulane University School of Medicine, New Orleans, USA
15:05 Questions and answers

15:10 Discussion

15:40 Break


SESSION 3.- PLANT-DERIVED ANTIBODIES

Chairperson Hilary KOPROWSKI, Jefferson University, Philadelphia, USA

16:10 Antibody engineering and new strategies for their production, including applications for HIV prevention and therapy
Julian MA, Guy's Hospital, London, UK
16:30 Questions and answers

16:35 Plant-derived antibodies for contraception and prevention of sexually transmitted diseases in humans
Kevin WHALEY, John Hopkins University, Baltimore, USA
16:55 Questions and answers

17:00 Expression of single chain antibodies in transgenic plants
Patricia GALEFFI, ENEA, Roma, Italy
17:20 Questions and answers

17:25 Production of human antibodies in eukaryotic algae
Steven MAYFIELD, The Scripps Research Institute, La Jolla, USA
17:45 Questions and answers

17:50 Hepatitis B antibody production in tobacco plants as an example of an integrated plantibody production system
Carlos BORROTO, Center for Genetic Engineering and Biotechnology, Habana, Cuba
Questions and answers

18:15 Discussion

18:45 Poster session and cocktail

19:30 Dinner


TUESDAY 23 MARCH 2004

SESSION 4.- PLANT-DERIVED CANDIDATE VACCINES


Part A: Veterinary vaccines

Chairperson Rose HAMMOND, USDA-ARS, Beltsville, USA

08:45 Production of foot-and-mouth disease vaccines in plants
Andres WIGDOROVITZ, Institute of Agricultural Technology, Argentina
09:05 Questions and answers

09:10 Production of poultry vaccines in plants
Steve R. WEBB, Dow Agrosciences, USA
09:30 Questions and answers

09:35 Conservation biology using immunocontraceptive vaccines to control feral animal populations
Ian POLKINGHORNE, University of Queensland, Australia

09:55 Questions and answers

10:00 Plant-derived vaccines for immunization against classical swine fever virus (CSFV) and F. hepatica
Andrzej B. LEGOCKI, Polish Academy of Sciences, Poznan, Poland
10:20 Questions and answers

10:25 Discussion: Prospects and impact of plant-derived vaccines for animals

10:45 Break

Human vaccines
Chairperson Stanley Plotkin, University of Pennsylvania, Philadelphia, USA

11:15 Virus-like particle expression and assembly in plants (with hepatitis B vaccine example)
Hugh MASON, Arizona State Univeristy, Tempe,USA
11:35 Questions and answers

11:40 Progress towards a plant-derived measles vaccine
Steve L. WESSELINGH, Macfarlane Burnet Institute, Melbourne, Australia
12:00 Questions and answers

12:05 Plant-derived vaccines against diarrheal diseases
Carol TACKET, Center for Vaccine Development, University of Maryland, Baltimore, USA
12:25 Questions and answers

12:30 Lunch

14:00 Progress towards a plant-derived rotavirus vaccine
William LANGRIDGE, Center for Molecular Biology and Gene Therapy, Loma Linda University, USA
14:20 Questions and answers

14:25 Challenges in creating a vaccine to prevent hepatitis E
Naokazu TAKEDA, National Institute of Infectious Diseases, Tokyo, Japan
14:45 Questions and answers

14:50 HIV and anthrax vaccines in plants
Alexander V. KARASEV, Thomas Jefferson University, Philadelphia, USA
15:10 Questions and answers

15:15 Human papilloma virus vaccine produced in plants
Martin MÜLLER, German Cancer Research, Heidelberg, Germany
15:35 Questions and answers

15:40 General discussion on vaccine production in plants
coordinated by Rose HAMMOND and Stanley PLOTKIN

16:00 Break


SESSION 5.- COMMERCIAL DEVELOPMENT OF PRODUCTION IN PLANTS


Chairperson Charles ARNTZEN, Arizona State University, Tempe, USA

16:30 Presentations by selected companies

17:30 Poster session

19:30 Dinner

WEDNESDAY 24 MARCH 2004

SESSION 5. (continued)- COMMERCIAL DEVELOPMENT

Chairperson Charles ARNTZEN, Arizona State University, Tempe, USA

08:30 Presentations by selected companies
Discussion


SESSION 6.- PUBLIC HEALTH PERSPECTIVES, REGULATORY CONSIDERATIONS AND ENVIRONMENTAL ISSUES

Chairperson Tikki PANG , WHO, Geneva, Switzerland

09:30 Environmental and political considerations concerning release of genetically modified crops
Chen ZHANGLIANG* Beijing University,China
09:50 Questions and answers

09:55 Ethics guidelines for the introduction of plant-derived vaccines in developing countries
David CASTLE, Univeristy of Guelph, Canada
10:15 Questions and answers

10:20 Break

10:45 Round-table 1 on Public Health, chaired by Tikki Pang, WHO Geneva, Switzerland
Richard JEFFERSON, Centre for Application of Molecular Biology to International Agriculture, Cambia, Australia; Regina RABINOVICH, Bill & Melinda Gates Foundation, Seattle,USA; Rachel CHIKWAMBA, Iowa State University, Ames, USA; Richard MAHONEY, Arizona State University, Tempe, USA; Varaprasada REDDY* Shanta Biotech, India

12:15 Lunch

Chairperson Marie Paule KIENY, WHO, Geneva,Switzerlandd

13:45 What is the advantage of plant-derived antibodies from the pharmaceutical industry perspective?
Richard McCLOSKEY, Centocor, Malvern, USA
14:05 Questions and answers

14:10 Round-table 2: Regulatory issues chaired by Marie-Paule KIENY, WHO, Geneva, Switzerland
Carlos BORROTO, Centre for Genetic Engineering and Biotechnology, Habana, Cuba; Chen ZHANGLIANG*, Beijing University China; Jon DAUGHERTY, FDA-CBER, Rockville, USA; Representatives of: USDA-APHIS,USA, John PURVES* EMEA (Europe)

15:30 Potential and limitations of vaccine and antibody production in plants. What are the most productive directions?
Roger BEACHY, Donald Danford PLant Science Center, Saint Louis, USA

15:50 Discussion/Conclusion

16:00 End of the meeting